CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
CORONANSE
CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 17% | 17% |
| - | - | 30% | 24% |
| - | - | - | - |
| 24% | 24% | 25% | 27% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
CORONA
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,773.4 | ₹425150 Cr | 38.77 | 8.29 | 58.23 | ₹11479 Cr |
| 10,037.5 | ₹266265 Cr | 91.03 | 34.04 | 128.41 | ₹2568 Cr |
| 4,738.5 | ₹176301 Cr | 83 | 14.04 | 106.21 | ₹2163 Cr |
| 2,323.8 | ₹125352 Cr | 93.56 | 8.17 | 33.94 | ₹889 Cr |
| 1,188.1 | ₹123591 Cr | 27.39 | 9.42 | 62.53 | ₹5040 Cr |
| 1,374 | ₹114351 Cr | 40.84 | 11.08 | 59.2 | ₹4196 Cr |
| 1,402 | ₹112474 Cr | 38.82 | 10.86 | 52.6 | ₹3879 Cr |
| 2,537.9 | ₹102315 Cr | 45.62 | 17.23 | 76.26 | ₹1913 Cr |
| 1,705 | ₹97757 Cr | 26.33 | 17.95 | 96.84 | ₹3505 Cr |
| 2,008.6 | ₹92007 Cr | 16.64 | 30.95 | 154.35 | ₹5333 Cr |
| 2,405.8 | ₹13910 Cr | 67.19 | 9.86 | 41.7 | ₹185 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| ₹441 Cr | ₹422 Cr | ₹353 Cr | ₹342 Cr | ₹361 Cr | ₹347 Cr | ₹294 Cr | ₹298 Cr | ₹314 Cr |
| ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹76 L | ₹2 Cr |
| ₹444 Cr | ₹426 Cr | ₹357 Cr | ₹345 Cr | ₹363 Cr | ₹349 Cr | ₹295 Cr | ₹298 Cr | ₹316 Cr |
| ₹360 Cr | ₹343 Cr | ₹301 Cr | ₹269 Cr | ₹292 Cr | ₹286 Cr | ₹250 Cr | ₹238 Cr | ₹256 Cr |
| ₹98 Cr | ₹96 Cr | ₹66 Cr | ₹85 Cr | ₹81 Cr | ₹72 Cr | ₹56 Cr | ₹70 Cr | ₹69 Cr |
| ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| ₹81 Cr | ₹80 Cr | ₹54 Cr | ₹55 Cr | ₹70 Cr | ₹61 Cr | ₹43 Cr | ₹58 Cr | ₹57 Cr |
| ₹60 Cr | ₹60 Cr | ₹45 Cr | ₹41 Cr | ₹52 Cr | ₹46 Cr | ₹31 Cr | ₹45 Cr | ₹43 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹61 Cr | ₹61 Cr | ₹61 Cr | ₹61 Cr |
| ₹686 Cr | ₹545 Cr | ₹419 Cr | ₹347 Cr |
| ₹686 Cr | ₹545 Cr | ₹419 Cr | ₹347 Cr |
| ₹747 Cr | ₹606 Cr | ₹480 Cr | ₹409 Cr |
| ₹0 | ₹16 Cr | ₹67 Cr | ₹0 |
| ₹12 Cr | ₹8 Cr | ₹4 Cr | -₹4 Cr |
| ₹19 Cr | ₹21 Cr | ₹23 Cr | ₹24 Cr |
| ₹66 Cr | ₹39 Cr | ₹32 Cr | ₹25 Cr |
| ₹97 Cr | ₹84 Cr | ₹126 Cr | ₹45 Cr |
| — | — | — | — |
| ₹147 Cr | ₹144 Cr | ₹114 Cr | ₹94 Cr |
| ₹46 Cr | ₹52 Cr | ₹50 Cr | ₹18 Cr |
| ₹127 Cr | ₹11 Cr | ₹31 Cr | ₹2 Cr |
| ₹135 Cr | ₹121 Cr | ₹73 Cr | ₹94 Cr |
| ₹455 Cr | ₹327 Cr | ₹269 Cr | ₹209 Cr |
| ₹1299 Cr | ₹1017 Cr | ₹875 Cr | ₹663 Cr |
| ₹1 Cr | ₹0 | ₹0 | ₹0 |
| ₹143 Cr | ₹63 Cr | ₹134 Cr | ₹2 Cr |
| — | — | — | — |
| ₹724 Cr | ₹503 Cr | ₹483 Cr | ₹256 Cr |
| ₹170 Cr | ₹133 Cr | ₹99 Cr | ₹72 Cr |
| ₹554 Cr | ₹370 Cr | ₹384 Cr | ₹185 Cr |
| ₹143 Cr | ₹186 Cr | ₹121 Cr | ₹65 Cr |
| ₹26 Cr | ₹26 Cr | ₹26 Cr | ₹26 Cr |
| ₹26 Cr | ₹26 Cr | ₹26 Cr | ₹26 Cr |
| ₹5 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr |
| ₹129 Cr | ₹10 L | ₹2 Cr | ₹15 Cr |
| ₹857 Cr | ₹591 Cr | ₹541 Cr | ₹299 Cr |
| — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹6 Cr |
| ₹125 Cr | ₹129 Cr | ₹98 Cr | ₹105 Cr |
| ₹146 Cr | ₹118 Cr | ₹100 Cr | ₹87 Cr |
| ₹44 Cr | ₹69 Cr | ₹70 Cr | ₹77 Cr |
| ₹2 Cr | ₹7 Cr | ₹4 Cr | ₹3 Cr |
| ₹125 Cr | ₹102 Cr | ₹63 Cr | ₹85 Cr |
| ₹442 Cr | ₹426 Cr | ₹335 Cr | ₹363 Cr |
| -₹13 Cr | ₹99 Cr | ₹66 Cr | ₹154 Cr |
| ₹1299 Cr | ₹1017 Cr | ₹875 Cr | ₹663 Cr |
| ₹122 | ₹99 | ₹79 | ₹67 |
| ₹122 | ₹99 | ₹79 | ₹67 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹240 Cr | ₹199 Cr | ₹118 Cr | ₹111 Cr |
| ₹44 Cr | ₹52 Cr | ₹47 Cr | ₹23 Cr |
| -₹6 Cr | -₹17 Cr | ₹9 Cr | -₹5 Cr |
| ₹279 Cr | ₹234 Cr | ₹175 Cr | ₹129 Cr |
| ₹229 Cr | ₹190 Cr | ₹157 Cr | ₹103 Cr |
| -₹256 Cr | -₹84 Cr | -₹267 Cr | -₹50 Cr |
| ₹25 Cr | -₹107 Cr | ₹99 Cr | -₹45 Cr |
| -₹1 Cr | ₹6 L | -₹11 Cr | ₹8 Cr |
| ₹3 Cr | ₹3 Cr | ₹14 Cr | ₹7 Cr |
| ₹0 | ₹0 | ₹20,000 | -₹4 L |
| ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹14 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 4 out of 9 oscillators
RSI
74.70Buy
STOCH %K
89.08Sell
MACD Level(12,26)
50.29Buy
Ultimate Oscillator
65.83Buy
Aroon Oscillator
30.00Sell
BOP
0.72Buy
CCI
230.94Sell
Williams %R
-10.92Sell
Momentum
346.20Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
2208.44Buy
SMA 9
2184.51Buy
EMA 21
2141.94Buy
SMA 21
2094.38Buy
EMA 50
2103.25Buy
SMA 50
2109.33Buy
EMA 200
1827.35Buy
SMA 200
1835.83Buy
WMA 20
2144.96Buy
Pivot
Pivot
Classic
Resistance 5
2748.90
Resistance 4
2622.80
Resistance 3
2496.70
Resistance 2
2370.60
Resistance 1
2321.10
Pivot
2244.50
Support 1
2195.00
Support 2
2118.40
Support 3
1992.30
Support 4
1866.20
Support 5
1740.10
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|
| 69.00% | 69.00% | 69.00% | 69.00% |
| 4.21% | 3.63% | 2.25% | 1.84% |
| 0.39% | 0.40% | 0.67% | 0.39% |
| 16.06% | 12.50% | 6.35% | 6.38% |
| 10.34% | 14.47% | 21.73% | 22.39% |
Bulk & block deals
Name
Sbi Mutual Fund
Sbi Mutual Fund
Amundi Funds Asia Equity Concentrated
Sepia Investments Limited
Factory Mutual Insurance Company
Abu Dhabi Investment Authority - Way
Tcw White Oak Emerging Markets Equity Fund
Hdfc Mutual Fund
Aditya Birla Sun Life Mutual Fund
Sepia Investments Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 10 Sep 2026 | Purchase | 139.40 Cr | ₹2,050 | 6.80 L | Bulk | 1.111836 | BSE |
| 10 Sep 2026 | Purchase | 176.30 Cr | ₹2,050 | 8.60 L | Bulk | 1.406146 | BSE |
| 10 Sep 2026 | Purchase | 63.96 Cr | ₹2,050 | 3.12 L | Bulk | 0.510137 | BSE |
| 10 Sep 2026 | Sell | 509.60 Cr | ₹2,050.32 | 24.85 L | Bulk | 4.063885 | BSE |
| 17 Jun 2026 | Purchase | 1.85 Cr | ₹1,730 | 10.67 K | Block | 0.017446 | NSE |
| 17 Jun 2026 | Purchase | 6.77 Cr | ₹1,730 | 39.13 K | Block | 0.06398 | NSE |
| 17 Jun 2026 | Purchase | 33.22 L | ₹1,730 | 1.92 K | Block | 0.003139 | NSE |
| 17 Jun 2026 | Purchase | 403.67 Cr | ₹1,730 | 23.33 L | Bulk | 3.815123 | NSE |
| 17 Jun 2026 | Purchase | 79.93 Cr | ₹1,730 | 4.62 L | Bulk | 0.755452 | NSE |
| 17 Jun 2026 | Sell | 748.91 Cr | ₹1,730 | 43.29 L | Bulk | 7.078051 | NSE |
Insider trading & SAST
Client name
Kirtisinh Manoharsinh Parmar
Kirtisinh Manoharsinh Parmar
Kirtisinh Manoharsinh Parmar
Kirtisinh Manoharsinh Parmar
Kirtisinh Manoharsinh Parmar
Ranjanben Kirtisinh Parmar
Apurvsinh Kirtisinh Parmar
Ranjanben Kirtisinh Parmar
Kirtisinh Manoharsinh Parmar
Kirtisinh Manoharsinh Parmar
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.00001 | 0 | 12.49 K | ₹2,082.33 | 6 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 197 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000002 | 0 | 2.08 K | ₹2,082 | 1 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 246 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000082 | 0 | 1.06 L | ₹2,122.52 | 50 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 156 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000057 | 0 | 73.41 K | ₹2,097.46 | 35 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 191 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000082 | 0 | 1.07 L | ₹2,142.56 | 50 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 106 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000147 | 0 | 1.91 L | ₹2,119.92 | 90 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 90 | Insider Trading | — | Equity |
| 19 Aug 2026 | Designated Person | Acquisition | 0.000082 | 0 | 1.03 L | ₹2,064.54 | 50 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 150 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000123 | 0 | 1.57 L | ₹2,089.73 | 75 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 165 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.00007 | 0 | 89.54 K | ₹2,082.37 | 43 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 341 | Insider Trading | — | Equity |
| 19 Aug 2026 | Immediate Relative | Acquisition | 0.000078 | 0 | 99.47 K | ₹2,072.33 | 48 | 05 Aug 2026 - 06 Aug 2026 | Market Purchase | 245 | Insider Trading | — | Equity |
CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Its diversified product
Corporate Actions
Date
Type
Details
Company details
CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
Corporate filings & documents
Announcements
Annual reports
No annual reports found
Concalls & investor presentations
CORONA Remedies Share Price
2405.80+134.20 (+5.91%)
+67.26% past 1 Year
News
Corona Remedies Reports Higher Second Quarter EBITDA Despite Slight Margin Decline
Equity
CORONA
Corona Remedies Reports Strong Year On Year Growth In Second Quarter Net Profit
Equity
CORONA
Corona Remedies Reports Strong Second Quarter Revenue Growth
Equity
CORONA
Corona Remedies Secures ANVISA GMP Certification For Bhayla Manufacturing Facilities
Equity
CORONA
Corona Remedies Receives Anvisa GMP Certification For Bhayla Manufacturing Facilities
Equity
CORONA
Corona Remedies to host analyst and investor meet on August 26, 2026
Equity
CORONA
Corona Remedies posts higher Q1 EBITDA and improved margin
Equity
CORONA
Corona Remedies reports strong year-on-year revenue growth in Q1 results
Equity
CORONA
Corona Remedies reports higher first quarter net profit on revenue growth
Equity
CORONA
Corona Remedies starts EU-GMP certified women’s hormone facility in Ahmedabad
Equity
CORONA
Corona Remedies informs about investor meetings
Equity
CORONA
CORONA Remedies rises on getting EU-GMP certification for Hormone manufacturing facility
Equity
CORONA
CORONA Remedies gets EU-GMP certification for Hormone manufacturing facility
Equity
CORONA
CORONA Remedies - Quaterly Results
Equity
CORONA
Corona Remedies Announces Final Dividend of Rs 10 Per Share
Equity
CORONA
Corona Remedies Reports Q4 EBITDA Growth to Rs 61 Crores, Margin Slightly Declines YoY
Equity
CORONA
Corona Remedies Q4 Net Profit Rises 44% YoY to Rs 45.10 Crores, Revenue Up 20% to Rs 353 Crores
Equity
CORONA
CORONA Remedies reports Profit after tax of 45.05 Crores, in the March 2026 quarter
Equity
CORONA
Corona Remedies Reports OCF to EBITDA Ratio of 87%, Enabling Further Acquisitions.
Equity
CORONA
Corona Remedies Reports Rs 112 Cr Cash as of Dec 31, Targets 20-25% CAGR for Wpladone Over 3 Years.
Equity
CORONA